Avandia rosiglitazone: Postmarketing study data

Last September, FDA significantly restricted the use of Avandia while EMA suspended the drug's marketing authorization due to cardiovascular safety concerns (see BioCentury, Sept. 27, 2010). GlaxoSmit...